Trial Profile
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Mavoglurant (Primary)
- Indications Fragile X syndrome; Mental retardation
- Focus Therapeutic Use
- Sponsors Novartis
- 12 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 14 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 20 Oct 2012 Planned number of patients changed from 160 to 180.